Navigation Links
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Date:7/29/2010

tatements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the anticipated action date for the FDA to complete its review of the Contrave NDA, the potential for, and timing of, approval for Contrave and the Company's belief that this product candidate may be an important therapeutic option in the treatment of obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave; reliance on third parties to assist with the development of Contrave; the potential for adverse safety findings relating to Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 10, 2010 and is available from
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... Mindray Medical International Limited (NYSE: MR ), ... worldwide, today announced shareholder resolutions adopted at its annual ... December 22, 2010. At the meeting, Mindray ... I-Yin Hsu and Mr. Wu Qiyao, each to serve ...
... Dec. 27, 2010 Cephalon, Inc. (Nasdaq: ... second Complete Response Letter from the U.S. Food and ... (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV] for the treatment ... disorder resulting from eastbound travel.  In its letter to ...
Cached Medicine Technology:Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder 2Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... esthetician, Karen,Dunlap, has developed an advanced anti-aging procedure ... most nutritious and powerful food,in the world -- ... and,nature, Dunlap discovered that topical application of the ... Her new signature facial, the,Acai Berry Anti-Aging Facial, ...
... 4 Trust for America,s,Health warns that the proposed ... and Prevention (CDC) in the president,s fiscal year 2009,budget ... the budget,for CDC would fall to a six year ... healthcare costs are skyrocketing, we should be,investing more to ...
... February 4, 2008 The U.S. Pharmacopeia (USP) ... Spanish edition of its core compendia, the United ... available for purchase. The official edition for 2008, ... more than 4,000 quality pharmaceuticals, excipients, dietary supplements, ...
... N.J., Feb. 4 Milestone Scientific,Inc. (OTC Bulletin ... today announced that Scott Mahnken has joined the,Company,s ... with,developing and managing a wide range of strategic ... brand awareness,and drive sales growth, Mahnken will report ...
... AUDUBON, Pa., Feb. 4 Globus Medical, Inc., the ... announced,record revenue for the year ending December 31, 2007. ... of 50 percent over the $82 million,it achieved in ... significant milestones achieved,by the Company during 2007. "This has ...
... on The Burden of Rheumatoid Arthritis and Patient Access ... Economics (Sweden), the University of Lund (Sweden) and the ... highest cost in rheumatoid arthritis results from patients having ... The study has just been published online in ...
Cached Medicine News:Health News:Breakthrough 'Acai Berry Anti-Aging Facial' Applies Benefits of Nature's Super-Food to the Skin 2Health News:Cuts to HHS Could Leave Americans' Health in Critical Condition, TFAH Says; New Poll Shows Americans Believe Disease Prevention is Key to Reducing Healthcare Costs 2Health News:USP publishes Spanish edition of United States Pharmacopeia and National Formulary 2Health News:Milestone Scientific Appoints Dental Industry Veteran Scott Mahnken as New Director of Marketing 2Health News:Milestone Scientific Appoints Dental Industry Veteran Scott Mahnken as New Director of Marketing 3Health News:Globus Medical Announces Record Revenue for 2007 2Health News:Rheumatoid arthritis sends many into early retirement 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States....
... The Surgical Foam Headrest automatically secures ... patient as comfortable as possible. Several ... adjust for any head size from ... be autoclaved when necessary. From surgical ...
... These focusing prismatic telescope are available in ... and 4.2x can be spectacle mounted or supplied ... The 8.25x is a hand held telescope. ,Small ... ideal for reading signposts, bus numbers, etc. ...
Medicine Products: